id	sid	eid	entity	type
bptjm-48	1	1	berkeley pharma tech journal	ORG
bptjm-48	1	2	neoantigen glioblastoma monoclonal antibodies	ORG
bptjm-48	1	3	may 8	DATE
bptjm-48	1	4	2023	CARDINAL
bptjm-48	1	5	july 14	DATE
bptjm-48	1	6	2023	CARDINAL
bptjm-48	1	7	december 30	DATE
bptjm-48	1	8	2023	CARDINAL
bptjm-48	1	9	4.0	CARDINAL
bptjm-48	1	10	yacoub alokam	PERSON
bptjm-48	1	11	suraj shah	PERSON
bptjm-48	1	12	almost half	CARDINAL
bptjm-48	7	1	1	CARDINAL
bptjm-48	8	1	1.1	CARDINAL
bptjm-48	10	1	1.2	CARDINAL
bptjm-48	13	1	1.3	CARDINAL
bptjm-48	14	1	pd-1/pd-l1	ORG
bptjm-48	17	1	1.4	CARDINAL
bptjm-48	17	2	berkeley pharma tech journal	ORG
bptjm-48	17	3	30	CARDINAL
bptjm-48	21	1	2	CARDINAL
bptjm-48	21	2	every year	DATE
bptjm-48	21	3	approximately 10,000	CARDINAL
bptjm-48	21	4	25%	PERCENT
bptjm-48	21	5	one-year	DATE
bptjm-48	21	6	6.8%	PERCENT
bptjm-48	21	7	5-year	DATE
bptjm-48	21	8	eight months	DATE
bptjm-48	22	1	1	CARDINAL
bptjm-48	22	2	0.15	CARDINAL
bptjm-48	22	3	100,000	CARDINAL
bptjm-48	22	4	15.03	CARDINAL
bptjm-48	22	5	100,000	CARDINAL
bptjm-48	22	6	berkeley pharma tech journal	ORG
bptjm-48	22	7	31	DATE
bptjm-48	22	8	between 75 and 84 years	DATE
bptjm-48	24	1	1	CARDINAL
bptjm-48	24	2	2	CARDINAL
bptjm-48	25	1	3	CARDINAL
bptjm-48	25	2	57%	PERCENT
bptjm-48	25	3	her2	PERSON
bptjm-48	25	4	13%	PERCENT
bptjm-48	25	5	1.6%	PERCENT
bptjm-48	25	6	3.2%	PERCENT
bptjm-48	25	7	pten	PERSON
bptjm-48	25	8	41%	PERCENT
bptjm-48	26	1	azd3579	PERSON
bptjm-48	27	1	bbb	ORG
bptjm-48	28	1	bbb	ORG
bptjm-48	28	2	pdx models.7 tucatinib	PERSON
bptjm-48	29	1	berkeley pharma tech journal	ORG
bptjm-48	29	2	32	CARDINAL
bptjm-48	30	1	bbb	ORG
bptjm-48	32	1	wen et al	PERSON
bptjm-48	33	1	3	CARDINAL
bptjm-48	34	1	neoantigen	ORG
bptjm-48	35	1	1988	DATE
bptjm-48	35	2	de plaen	PERSON
bptjm-48	38	1	first	ORDINAL
bptjm-48	40	1	berkeley pharma tech journal	ORG
bptjm-48	40	2	33	CARDINAL
bptjm-48	41	1	neoantigens	PERSON
bptjm-48	42	1	1988	DATE
bptjm-48	42	2	de plaen	PERSON
bptjm-48	45	1	first	ORDINAL
bptjm-48	48	1	2	CARDINAL
bptjm-48	48	2	neoantigens berkeley pharma tech journal	ORG
bptjm-48	48	3	34	CARDINAL
bptjm-48	48	4	6.11	CARDINAL
bptjm-48	49	1	two	CARDINAL
bptjm-48	50	1	hla-a	PERSON
bptjm-48	50	2	hla-c	PERSON
bptjm-48	50	3	cd8+ t-cells.11	ORG
bptjm-48	50	4	hla-dr	PERSON
bptjm-48	50	5	hla-dq	PERSON
bptjm-48	50	6	hla-dp	PERSON
bptjm-48	51	1	3	CARDINAL
bptjm-48	51	2	three	CARDINAL
bptjm-48	59	1	berkeley pharma tech journal	ORG
bptjm-48	59	2	35	CARDINAL
bptjm-48	62	1	hpv)which	GPE
bptjm-48	62	2	non-hodgkin's	ORG
bptjm-48	63	1	body.14	LOC
bptjm-48	66	1	4	CARDINAL
bptjm-48	66	2	4.1	CARDINAL
bptjm-48	70	1	berkeley pharma tech journal	ORG
bptjm-48	70	2	36 http://www.cta.lncc.br/	QUANTITY
bptjm-48	70	3	4	CARDINAL
bptjm-48	71	1	4.2	CARDINAL
bptjm-48	73	1	fda	ORG
bptjm-48	74	1	three	CARDINAL
bptjm-48	77	1	cells.16	ORG
bptjm-48	78	1	berkeley pharma tech journal	ORG
bptjm-48	78	2	37	CARDINAL
bptjm-48	79	1	neoantigen identi	PERSON
bptjm-48	80	1	one	CARDINAL
bptjm-48	81	1	wes	PERSON
bptjm-48	81	2	1-5%	PERCENT
bptjm-48	81	3	approximately 85%	PERCENT
bptjm-48	83	1	one	CARDINAL
bptjm-48	83	2	three	CARDINAL
bptjm-48	84	1	two	CARDINAL
bptjm-48	84	2	hilf et al	PERSON
bptjm-48	85	1	30568303	DATE
bptjm-48	86	1	30568305	DATE
bptjm-48	86	2	2019	DATE
bptjm-48	86	3	hilf	PRODUCT
bptjm-48	88	1	apvac1	PERSON
bptjm-48	88	2	1	CARDINAL
bptjm-48	88	3	apvac2	GPE
bptjm-48	89	1	apvac1	PERSON
bptjm-48	89	2	apvac2	ORG
bptjm-48	89	3	29 months	DATE
bptjm-48	89	4	14.2	CARDINAL
bptjm-48	89	5	berkeley pharma tech journal	ORG
bptjm-48	89	6	38 months	DATE
bptjm-48	90	1	ten	CARDINAL
bptjm-48	91	1	16.8 months	DATE
bptjm-48	91	2	7.6	CARDINAL
bptjm-48	91	3	reardon et al	GPE
bptjm-48	92	1	nct02287428	ORG
bptjm-48	93	1	second	ORDINAL
bptjm-48	93	2	two weeks	DATE
bptjm-48	93	3	two years	DATE
bptjm-48	93	4	third	ORDINAL
bptjm-48	93	5	about three weeks	DATE
bptjm-48	93	6	two years	DATE
bptjm-48	93	7	fourth	ORDINAL
bptjm-48	93	8	two weeks	DATE
bptjm-48	93	9	three weeks	DATE
bptjm-48	93	10	six	CARDINAL
bptjm-48	94	1	at least ten	CARDINAL
bptjm-48	94	2	1	CARDINAL
bptjm-48	94	3	12 weeks	DATE
bptjm-48	94	4	1	CARDINAL
bptjm-48	95	1	ifn-γ	PERSON
bptjm-48	95	2	week 16	DATE
bptjm-48	95	3	eight months	DATE
bptjm-48	95	4	1	CARDINAL
bptjm-48	95	5	1a	CARDINAL
bptjm-48	95	6	1b	CARDINAL
bptjm-48	95	7	1c	CARDINAL
bptjm-48	95	8	eleven months	DATE
bptjm-48	95	9	berkeley pharma tech journal	ORG
bptjm-48	95	10	39	CARDINAL
bptjm-48	95	11	1d).22	DATE
bptjm-48	96	1	4.3	CARDINAL
bptjm-48	96	2	two	CARDINAL
bptjm-48	99	1	three	CARDINAL
bptjm-48	100	1	one	CARDINAL
bptjm-48	101	1	mhc	PRODUCT
bptjm-48	102	1	third	ORDINAL
bptjm-48	102	2	cd8+ t cells.23 berkeley pharma tech journal	ORG
bptjm-48	102	3	40	CARDINAL
bptjm-48	102	4	5	CARDINAL
bptjm-48	103	1	johanns et al	LOC
bptjm-48	103	2	2000	DATE
bptjm-48	104	1	gnos-pv01 + ino-9012	PERSON
bptjm-48	105	1	5.0	CARDINAL
bptjm-48	105	2	the u.s. department of health and human services	ORG
bptjm-48	106	1	three	CARDINAL
bptjm-48	107	1	berkeley pharma tech journal	ORG
bptjm-48	107	2	41	CARDINAL
bptjm-48	108	1	johanns et al	LOC
bptjm-48	112	1	one	CARDINAL
bptjm-48	113	1	durvalumab	PERSON
bptjm-48	114	1	27	CARDINAL
bptjm-48	114	2	johanns	NORP
bptjm-48	116	1	two	CARDINAL
bptjm-48	116	2	di�erences.23	ORG
bptjm-48	116	3	two	CARDINAL
bptjm-48	119	1	apcs	ORG
bptjm-48	120	1	berkeley pharma tech journal	ORG
bptjm-48	120	2	42	CARDINAL
bptjm-48	120	3	6	CARDINAL
bptjm-48	122	1	desjardins et al	PERSON
bptjm-48	122	2	desjardins et al	PERSON
bptjm-48	124	1	4.4	CARDINAL
bptjm-48	124	2	dcs	ORG
bptjm-48	126	1	dcs	ORG
bptjm-48	126	2	berkeley pharma tech journal	ORG
bptjm-48	127	1	43	DATE
bptjm-48	127	2	ctl	ORG
bptjm-48	128	1	taas	PERSON
bptjm-48	129	1	dcs	ORG
bptjm-48	130	1	dcs	ORG
bptjm-48	130	2	nonlymphoid	GPE
bptjm-48	131	1	dcs	ORG
bptjm-48	131	2	dc	GPE
bptjm-48	131	3	7	CARDINAL
bptjm-48	133	1	tmb	ORG
bptjm-48	133	2	about 10	CARDINAL
bptjm-48	133	3	tmb	ORG
bptjm-48	134	1	berkeley pharma tech journal	ORG
bptjm-48	134	2	44	DATE
bptjm-48	134	3	35661819	CARDINAL
bptjm-48	136	1	multiplex immunohistochemistry	ORG
bptjm-48	136	2	ihc	ORG
bptjm-48	137	1	two months	DATE
bptjm-48	139	1	25 months	DATE
bptjm-48	142	1	approximately 35.3%	PERCENT
bptjm-48	142	2	86.5%	PERCENT
bptjm-48	142	3	0%	PERCENT
bptjm-48	142	4	16.8%	PERCENT
bptjm-48	142	5	four	CARDINAL
bptjm-48	143	1	4.5	CARDINAL
bptjm-48	146	1	berkeley pharma tech journal	ORG
bptjm-48	146	2	45	CARDINAL
bptjm-48	146	3	8	CARDINAL
bptjm-48	148	1	icis	PERSON
bptjm-48	149	1	cd28	ORG
bptjm-48	149	2	cd80	PRODUCT
bptjm-48	149	3	cd86	PRODUCT
bptjm-48	151	1	cd80	PRODUCT
bptjm-48	151	2	cd86	PRODUCT
bptjm-48	153	1	berkeley pharma tech journal	ORG
bptjm-48	153	2	46	CARDINAL
bptjm-48	155	1	anti-pd-l1	NORP
bptjm-48	156	1	9	CARDINAL
bptjm-48	157	1	anti-pd-l1	NORP
bptjm-48	157	2	pdl1	NORP
bptjm-48	158	1	anti-pd-l1	NORP
bptjm-48	164	1	berkeley pharma tech journal	ORG
bptjm-48	164	2	47	CARDINAL
bptjm-48	165	1	two	CARDINAL
bptjm-48	165	2	two	CARDINAL
bptjm-48	166	1	fc	NORP
bptjm-48	167	1	fc	NORP
bptjm-48	167	2	fc	NORP
bptjm-48	174	1	today	DATE
bptjm-48	174	2	berkeley pharma tech journal	ORG
bptjm-48	174	3	48	CARDINAL
bptjm-48	175	1	ipilimumab	PERSON
bptjm-48	175	2	atezolizumab	PERSON
bptjm-48	175	3	glioblastoma.32	CARDINAL
bptjm-48	176	1	10	CARDINAL
bptjm-48	177	1	berkeley pharma tech journal	ORG
bptjm-48	177	2	49	CARDINAL
bptjm-48	177	3	11	CARDINAL
bptjm-48	180	1	three	CARDINAL
bptjm-48	180	2	1	CARDINAL
bptjm-48	180	3	2	CARDINAL
bptjm-48	180	4	3	CARDINAL
bptjm-48	182	1	one	CARDINAL
bptjm-48	182	2	fda	ORG
bptjm-48	183	1	pd-l1	GPE
bptjm-48	184	1	240 mg	QUANTITY
bptjm-48	184	2	2 weeks	DATE
bptjm-48	184	3	480	CARDINAL
bptjm-48	184	4	4 weeks	DATE
bptjm-48	184	5	3 mg/kg	QUANTITY
bptjm-48	184	6	under 40kg	QUANTITY
bptjm-48	186	1	berkeley pharma tech journal	ORG
bptjm-48	186	2	50	CARDINAL
bptjm-48	186	3	mice.14	LOC
bptjm-48	187	1	3mg	QUANTITY
bptjm-48	187	2	every 2 weeks	DATE
bptjm-48	187	3	anti-pd-l1	NORP
bptjm-48	189	1	ctc	ORG
bptjm-48	191	1	idh1	ORG
bptjm-48	193	1	one	CARDINAL
bptjm-48	193	2	daily	DATE
bptjm-48	195	1	fda	ORG
bptjm-48	196	1	cd80	PRODUCT
bptjm-48	196	2	cd86	PRODUCT
bptjm-48	196	3	fda	ORG
bptjm-48	197	1	berkeley pharma tech journal	ORG
bptjm-48	197	2	51	CARDINAL
bptjm-48	198	1	ipilimumab	PERSON
bptjm-48	200	1	4.6	CARDINAL
bptjm-48	202	1	them.39,40,41	PERSON
bptjm-48	202	2	berkeley pharma tech journal	ORG
bptjm-48	202	3	52	CARDINAL
bptjm-48	202	4	12	CARDINAL
bptjm-48	205	1	two	CARDINAL
bptjm-48	209	1	berkeley pharma tech journal	ORG
bptjm-48	210	1	53 https://clinicaltrials.gov/ct2/show/nct05685004?term=nct05685004&draw=2&rank=1	QUANTITY
bptjm-48	212	1	one	CARDINAL
bptjm-48	212	2	13	CARDINAL
bptjm-48	213	1	2	CARDINAL
bptjm-48	214	1	2	CARDINAL
bptjm-48	215	1	ipilimumab	PERSON
bptjm-48	215	2	2	CARDINAL
bptjm-48	215	3	berkeley pharma tech journal	ORG
bptjm-48	215	4	54	CARDINAL
bptjm-48	215	5	https://clinicaltrials.gov/ct2/show/record/nct04003649?term=car+t&recrs=ad&cond=glioblastoma&draw=4&rank=5	ORG
bptjm-48	217	1	4.7	CARDINAL
bptjm-48	220	1	7%	PERCENT
bptjm-48	221	1	system.48	PERSON
bptjm-48	221	2	1	CARDINAL
bptjm-48	221	3	1	CARDINAL
bptjm-48	221	4	2,3	CARDINAL
bptjm-48	221	5	ido	ORG
bptjm-48	223	1	pd-l1-	GPE
bptjm-48	223	2	berkeley pharma tech journal	ORG
bptjm-48	223	3	55	CARDINAL
bptjm-48	224	1	5	CARDINAL
bptjm-48	226	1	neoantigens	PERSON
bptjm-48	231	1	one	CARDINAL
bptjm-48	234	1	berkeley pharma tech journal	ORG
bptjm-48	235	1	56	CARDINAL
bptjm-48	242	1	6	CARDINAL
bptjm-48	245	1	neoantigen	ORG
bptjm-48	246	1	ctl	ORG
bptjm-48	247	1	hilf et al	PERSON
bptjm-48	247	2	berkeley pharma tech journal	ORG
bptjm-48	247	3	57	CARDINAL
bptjm-48	251	1	johanns et al	LOC
bptjm-48	252	1	sayour et al	PERSON
bptjm-48	253	1	johanns et al	LOC
bptjm-48	261	1	ipilimumab	PERSON
bptjm-48	261	2	berkeley pharma tech journal	ORG
bptjm-48	261	3	58	CARDINAL
bptjm-48	268	1	first	ORDINAL
bptjm-48	274	1	berkeley pharma tech journal	ORG
bptjm-48	274	2	59	CARDINAL
bptjm-48	274	3	1	CARDINAL
bptjm-48	275	1	wirsching hg	PERSON
bptjm-48	275	2	weller m. glioblastoma.handb clin neurol	PERSON
bptjm-48	276	1	2016;134:381-397	CARDINAL
bptjm-48	277	1	doi:10.1016	GPE
bptjm-48	277	2	0	CARDINAL
bptjm-48	277	3	american	NORP
bptjm-48	277	4	learnmore	PERSON
bptjm-48	278	1	august 22	DATE
bptjm-48	278	2	2022	CARDINAL
bptjm-48	279	1	february 16	DATE
bptjm-48	279	2	2023	CARDINAL
bptjm-48	280	1	stoyanov gs	PERSON
bptjm-48	280	2	ghenev p	ORG
bptjm-48	282	1	2018;35(3):27	LANGUAGE
bptjm-48	282	2	4	CARDINAL
bptjm-48	282	3	tamimi af	PERSON
bptjm-48	282	4	juweidm.	PERSON
bptjm-48	285	1	codon publications	PERSON
bptjm-48	285	2	2017	CARDINAL
bptjm-48	286	1	3	CARDINAL
bptjm-48	286	2	2023	CARDINAL
bptjm-48	287	1	0003/ 5	DATE
bptjm-48	288	1	february 16	DATE
bptjm-48	288	2	2023	CARDINAL
bptjm-48	289	1	6	CARDINAL
bptjm-48	290	1	davis	PERSON
bptjm-48	292	1	clin	PERSON
bptjm-48	293	1	2016;20(5):s2	CARDINAL
bptjm-48	295	1	wang z	PERSON
bptjm-48	295	2	peet np	PERSON
bptjm-48	295	3	zhang p	PERSON
bptjm-48	295	4	jiang y	PERSON
bptjm-48	295	5	rong l.	PERSON
bptjm-48	297	1	2021;20(9):1521-1532	DATE
bptjm-48	298	1	md	GPE
bptjm-48	300	1	2022	CARDINAL
bptjm-48	301	1	5	CARDINAL
bptjm-48	301	2	2023	CARDINAL
bptjm-48	302	1	9	CARDINAL
bptjm-48	302	2	de plaen e	PERSON
bptjm-48	302	3	van pel	ORG
bptjm-48	302	4	tumantigen p91a	PERSON
bptjm-48	302	5	identi	PERSON
bptjm-48	303	1	sci u s a. 1988;85(7):2274-2278	ORG
bptjm-48	306	1	curr opin	PERSON
bptjm-48	306	2	immunol	PERSON
bptjm-48	307	1	1999;11(2):203-208	CARDINAL
bptjm-48	307	2	doi:10.1016	PERSON
bptjm-48	307	3	11	CARDINAL
bptjm-48	308	1	hutchison s	ORG
bptjm-48	308	2	pritchard al	PERSON
bptjm-48	311	1	2018;29(11	CARDINAL
bptjm-48	312	1	z. neoantigens	PERSON
bptjm-48	314	1	2017;8:1679	DATE
bptjm-48	315	1	2017 nov 28	DATE
bptjm-48	316	1	doi:10.3389/	CARDINAL
bptjm-48	317	1	correale p	PERSON
bptjm-48	317	2	walmsley k	PERSON
bptjm-48	320	1	1997;89(4):293-300	CARDINAL
bptjm-48	321	1	guo z	PERSON
bptjm-48	321	2	chen	PERSON
bptjm-48	324	1	2022;6(1):1-7	CARDINAL
bptjm-48	324	2	doi:10.1038	ORG
bptjm-48	324	3	berkeley pharma tech journal	ORG
bptjm-48	325	1	60	CARDINAL
bptjm-48	326	1	15	CARDINAL
bptjm-48	326	2	malonis rj	PERSON
bptjm-48	326	3	lai jr	PERSON
bptjm-48	326	4	vergnolle o.	PERSON
bptjm-48	328	1	2020;120(6):3210-3229	CARDINAL
bptjm-48	330	1	li w	PERSON
bptjm-48	330	2	joshi md	PERSON
bptjm-48	330	3	ramsey kh	PERSON
bptjm-48	330	4	murthy ak.	PERSON
bptjm-48	331	1	2014;2(3):515-536	CARDINAL
bptjm-48	333	1	wang c	PERSON
bptjm-48	334	1	neoantigen discovery	PERSON
bptjm-48	336	1	2022;550:215945	CARDINAL
bptjm-48	337	1	doi:10.1016	GPE
bptjm-48	337	2	18	CARDINAL
bptjm-48	338	1	3wes	CARDINAL
bptjm-48	340	1	23	CARDINAL
bptjm-48	340	2	2023	CARDINAL
bptjm-48	344	1	2013;98(6):236-238	CARDINAL
bptjm-48	346	1	hilf n	PERSON
bptjm-48	348	1	2019;565(7738):240-245	CARDINAL
bptjm-48	349	1	doi:10.1038	ORG
bptjm-48	350	1	keskin db	PERSON
bptjm-48	350	2	anandappa aj	PERSON
bptjm-48	350	3	sun j	PERSON
bptjm-48	352	1	2019;565(7738):234	CARDINAL
bptjm-48	352	2	doi:10.1038	ORG
bptjm-48	352	3	018-0792-9 22	CARDINAL
bptjm-48	353	1	mddr	PERSON
bptjm-48	355	1	2022	CARDINAL
bptjm-48	356	1	2	CARDINAL
bptjm-48	356	2	2023	CARDINAL
bptjm-48	358	1	qin	PERSON
bptjm-48	359	1	xia f	PERSON
bptjm-48	359	2	chen h	PERSON
bptjm-48	362	1	2021;9:633776	CARDINAL
bptjm-48	363	1	2021may 25	LAW
bptjm-48	363	2	24	CARDINAL
bptjm-48	364	1	bai h	ORG
bptjm-48	364	2	lester gms	PERSON
bptjm-48	364	3	dean da	PERSON
bptjm-48	365	1	biosci	PERSON
bptjm-48	365	2	2017;37(6):bsr20160616	CARDINAL
bptjm-48	366	1	2017 nov 29	DATE
bptjm-48	367	1	25	CARDINAL
bptjm-48	368	1	washington university school of medicine	ORG
bptjm-48	370	1	2023	CARDINAL
bptjm-48	371	1	5	CARDINAL
bptjm-48	371	2	2023	CARDINAL
bptjm-48	372	1	26	CARDINAL
bptjm-48	373	1	washington university school of medicine	ORG
bptjm-48	375	1	2023	CARDINAL
bptjm-48	376	1	5	CARDINAL
bptjm-48	376	2	2023	CARDINAL
bptjm-48	377	1	27	CARDINAL
bptjm-48	378	1	washington university school of medicine	ORG
bptjm-48	379	1	1	CARDINAL
bptjm-48	379	2	neoantigen dnavaccine	ORG
bptjm-48	379	3	neoantigen dnavaccine	ORG
bptjm-48	380	1	2023	CARDINAL
bptjm-48	381	1	5	CARDINAL
bptjm-48	381	2	2023	CARDINAL
bptjm-48	382	1	28	CARDINAL
bptjm-48	383	1	university of florida	ORG
bptjm-48	384	1	berkeley pharma tech journal	ORG
bptjm-48	387	1	2023	CARDINAL
bptjm-48	388	1	may 5	DATE
bptjm-48	388	2	2023	CARDINAL
bptjm-48	389	1	29	CARDINAL
bptjm-48	390	1	ph.d ga	ORG
bptjm-48	391	1	2022	CARDINAL
bptjm-48	392	1	5	CARDINAL
bptjm-48	392	2	2023	CARDINAL
bptjm-48	393	1	30	CARDINAL
bptjm-48	394	1	saadeldin mk	PERSON
bptjm-48	394	2	abdel-aziz ak	PERSON
bptjm-48	394	3	abdellatif a. dendritic	ORG
bptjm-48	394	4	the beginning of the end	DATE
bptjm-48	394	5	covid-19	PERSON
bptjm-48	397	1	doi:10.1016	GPE
bptjm-48	397	2	31	CARDINAL
bptjm-48	398	1	datsi	PERSON
bptjm-48	398	2	sorg rv	PERSON
bptjm-48	400	1	2021;12	CARDINAL
bptjm-48	401	1	23	CARDINAL
bptjm-48	401	2	2023	CARDINAL
bptjm-48	403	1	021.770390 32	CARDINAL
bptjm-48	404	1	isaacsson velho p	PERSON
bptjm-48	406	1	rev clin	PERSON
bptjm-48	407	1	2018;11(5):475-486	CARDINAL
bptjm-48	408	1	33	CARDINAL
bptjm-48	409	1	dunn gp	PERSON
bptjm-48	410	1	first	ORDINAL
bptjm-48	412	1	2020;117(1):45	CARDINAL
bptjm-48	413	1	34	CARDINAL
bptjm-48	414	1	malik	PERSON
bptjm-48	414	2	ghatol a.	PERSON
bptjm-48	416	1	2023	CARDINAL
bptjm-48	417	1	april 8	DATE
bptjm-48	417	2	2023	CARDINAL
bptjm-48	418	1	35	CARDINAL
bptjm-48	419	1	aziz m	PERSON
bptjm-48	422	1	2023	CARDINAL
bptjm-48	423	1	april 8	DATE
bptjm-48	423	2	2023	CARDINAL
bptjm-48	424	1	36	CARDINAL
bptjm-48	425	1	clinica universidad de navarra	ORG
bptjm-48	426	1	2017	CARDINAL
bptjm-48	427	1	5	CARDINAL
bptjm-48	427	2	2023	CARDINAL
bptjm-48	429	1	37	DATE
bptjm-48	429	2	national cancer institute	ORG
bptjm-48	429	3	nci	ORG
bptjm-48	431	1	2023	CARDINAL
bptjm-48	432	1	5	CARDINAL
bptjm-48	432	2	2023	CARDINAL
bptjm-48	433	1	38	CARDINAL
bptjm-48	434	1	nyu langone health.a	ORG
bptjm-48	434	2	ipilimumab	PERSON
bptjm-48	435	1	2022	CARDINAL
bptjm-48	436	1	5	CARDINAL
bptjm-48	436	2	2023	CARDINAL
bptjm-48	437	1	39	CARDINAL
bptjm-48	438	1	yamamoto tn	PERSON
bptjm-48	438	2	kishton rj	PERSON
bptjm-48	438	3	restifo np	PERSON
bptjm-48	439	1	2019;25(10):1488-1499	CARDINAL
bptjm-48	440	1	doi:10.1038	ORG
bptjm-48	441	1	yoonws	PERSON
bptjm-48	441	2	chung ds	PERSON
bptjm-48	442	1	korean	NORP
bptjm-48	443	1	january 2	DATE
bptjm-48	443	2	2023	CARDINAL
bptjm-48	444	1	january 30	DATE
bptjm-48	444	2	2023	CARDINAL
bptjm-48	445	1	https://www.jkns.or.kr/journal/view.php?number=75	CARDINAL
bptjm-48	445	2	berkeley pharma tech journal	ORG
bptjm-48	445	3	62	DATE
bptjm-48	445	4	https://www.frontiersin.org/articles/10.3389/fimmu.2021.770390 https://www.frontiersin.org/articles/10.3389/fimmu.2021.770390 https://www.frontiersin.org/articles/10.3389/fimmu.2021.770390	PERSON
bptjm-48	447	1	91 41	CARDINAL
bptjm-48	449	1	j. 2021;11(4):1-11	PERSON
bptjm-48	450	1	doi:10.1038	ORG
bptjm-48	451	1	fang x	PERSON
bptjm-48	451	2	guo z	PERSON
bptjm-48	451	3	liang j	PERSON
bptjm-48	451	4	neoantigens	PERSON
bptjm-48	451	5	immunotherapy.oncol lett.	PERSON
bptjm-48	452	1	2022;23(3):88	DATE
bptjm-48	453	1	doi:10.3892	ORG
bptjm-48	454	1	zhao y, deng j	PERSON
bptjm-48	454	2	rao s	PERSON
bptjm-48	456	1	2022;14(17):4160	CARDINAL
bptjm-48	457	1	2b	CARDINAL
bptjm-48	458	1	2023	CARDINAL
bptjm-48	459	1	5	CARDINAL
bptjm-48	459	2	2023	CARDINAL
bptjm-48	460	1	45	CARDINAL
bptjm-48	461	1	kessler af	PERSON
bptjm-48	461	2	monoranu cm	PERSON
bptjm-48	461	3	ernestus ri	GPE
bptjm-48	463	1	2019;11(12):1837	CARDINAL
bptjm-48	463	2	46	CARDINAL
bptjm-48	464	1	alnefaie	ORG
bptjm-48	466	1	2022;10	CARDINAL
bptjm-48	466	2	april 8	DATE
bptjm-48	466	3	2023	CARDINAL
bptjm-48	467	1	https://www.frontiersin.org/articles/10.3389/fbioe.20	CARDINAL
bptjm-48	467	2	22.797440	CARDINAL
bptjm-48	468	1	brown ce	PERSON
bptjm-48	468	2	aguilar b	PERSON
bptjm-48	468	3	starr	PERSON
bptjm-48	469	1	2018;26(1):31-44	DATE
bptjm-48	470	1	doi:10.1016	GPE
bptjm-48	470	2	48	DATE
bptjm-48	471	1	hodge jw	PERSON
bptjm-48	471	2	ardiani	GPE
bptjm-48	471	3	kwilas ar	GPE
bptjm-48	471	4	gameiro s.	PERSON
bptjm-48	472	1	semin oncol	PERSON
bptjm-48	474	1	49	CARDINAL
bptjm-48	475	1	liu cj	PERSON
bptjm-48	475	2	blaha	PERSON
bptjm-48	476	1	oncol	TIME
bptjm-48	477	1	2020;22(9):1276-1288	DATE
bptjm-48	478	1	50	CARDINAL
bptjm-48	479	1	rosenberg sa	PERSON
bptjm-48	479	2	yang jc	PERSON
bptjm-48	479	3	restifo np	PERSON
bptjm-48	480	1	2004;10(9):909	CARDINAL
bptjm-48	481	1	doi:10.1038	ORG
bptjm-48	482	1	kjeldsen jw	PERSON
bptjm-48	482	2	lorentzen	PERSON
bptjm-48	483	1	1/2	CARDINAL
bptjm-48	483	2	ido/pd-l1	ORG
bptjm-48	484	1	2021;27(12):2212-2223	CARDINAL
bptjm-48	485	1	doi:10.1038	ORG
bptjm-48	485	2	52	CARDINAL
bptjm-48	486	1	pd-l1/ido	ORG
bptjm-48	486	2	berkeley pharma tech journal	ORG
bptjm-48	486	3	63 https://www.jkns.or.kr/journal/view.php?number=7591	TIME
bptjm-48	487	1	https://doi.org/10.3390/cancers11121837 https://www.frontiersin.org/articles/10.3389/fbioe.2022.797440 https://www.frontiersin.org/articles/10.3389/fbioe.2022.797440 https://www.frontiersin.org/articles/10.3389/fbioe.2022.797440	ORG
bptjm-48	487	2	https://doi.org/10.1038/s41591-021-01544-x	PRODUCT
bptjm-48	488	1	2022	CARDINAL
bptjm-48	489	1	5	CARDINAL
bptjm-48	489	2	2023	CARDINAL
bptjm-48	490	1	53	DATE
bptjm-48	491	1	chen	PERSON
bptjm-48	492	1	2021	CARDINAL
bptjm-48	494	1	2021;20(7):827-837	CARDINAL
bptjm-48	495	1	berkeley pharma tech journal	ORG
bptjm-48	495	2	64	CARDINAL